ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2020

A cost-utility analysis of phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction.

Svenn Alexander Hansen et al.PubMed ↗Publisher ↗

No numbers read from the abstract.